Evidence map›Paper›PMID 40360233›Full record

ArticleGut2025

LECT2-PHB2 axis: a new mechanistic insight and therapeutic opportunity in alcohol-associated hepatitis.

Hui Li, Meiyi Song, Phillip B Hylemon, Huiping Zhou

Abstract read
In one paragraph

Article in Gut, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hui LiMicrobiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Meiyi SongMicrobiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Phillip B HylemonMicrobiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Huiping ZhouMicrobiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA Huiping.Zhou@vcuhealth.org.ORCID http://orcid.org/0000-0002-0050-372X

Funding

Mouse Model and Pathological Analysis CoreP01CA275740 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Nolan Wages · 2024 to 2026
$10.6M
Circular RNAs in Cholestatic Liver DiseasesR01DK139587 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HUIPING ZHOU · 2024 to 2026
$2.2M
Sphingolipids in alcoholic liver diseaseR01AA030180 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI PHILLIP B HYLEMON, HUIPING ZHOU · 2023 to 2026
$2.1M
LncRNA H19 in Cholestatic Liver DiseasesR56DK115377 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI HYLEMON, PHILLIP B, ZHOU, HUIPING ROSE · 2023 to 2023
$630k
BLRD VA I01 BX005730BLRD VA IK6 BX004477NCI NIH HHS P01 CA275740NIAAA NIH HHS R01 AA030180NIDDK NIH HHS R01 DK139587NIDDK NIH HHS R56 DK115377
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ALCOHOLIC LIVER DISEASEINFLAMMATORY MECHANISMSLIVER

Identifiers

PMID40360233
PMCPMC12353532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.